2019

article thumbnail

What Are The Reasons Of Popularization And Future Aspects Of Pharma Franchise Business?

Fossil Remedies

POPULARIZATION AND FUTURE ASPECTS OF PHARMA FRANCHISE BUSINESS. Are you planning to launch a pharma franchise business? If yes, then it is essential to know everything about its prospects and reasons for its popularity. What are the primary reasons that affect it? Experts say that pharma franchise business is different, and hence, it is all the more important to understand it in detail.

75
article thumbnail

Faces of Fuld: Q&A with Kimberlee Luce, Senior Director, Consumer Products + Retail

Fuld

Kimberlee Luce has more than 20 years of experience in business research and consulting and has a unique blend of expertise rooted in opportunity analysis, competitor strategy and building effective distribution models in highly fragmented markets. She has provided market and competitive intelligence to some of the world’s largest and most ambitious companies taking her to places as diverse as Peru, Nigeria and China.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

2019 in Review for The Digital Apothecary

The Digital Apothecary

Well, 2019 is drawing to a close, and I thought it would be good to give a recap to what I've worked on with The Digital Apothecary this year. Overall, I would say it's been one of my most successful years, with over 40,000 visitors - which as a blog that puts out only a few articles a week - I am quite happy about it. Surprisingly, I have found LinkedIn to be one of my most abundant sources of engagements this year, and I think I will start pushing more content on that side.

52
article thumbnail

The Science of Healthcare Congresses

pharmaphorum

Research from Ashfield Meetings & Events clearly demonstrates that face-to-face meetings and events form a major part of continuing medical education (CME). National and international congresses have been identified as the primary event to attend by HCPs. But what makes congresses such a valuable education channel for time-restricted physicians? This pharmaphorum webinar, in association with Ashfield Meetings & Events, will dive into a unique study of HCP educational and behavioural preferences

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

How to Seize New Pharmacy Opportunity in the Pharma Industry

The Nontraditional Pharmacist

Will Soliman, Chairman and CEO, of Accreditation Council for Medical Affairs (ACMA) discusses the exciting opportunities available to pharmacists in the pharma industry and how to pursue them. Name: William Soliman. Title: Chairman, Accreditation Council for Medical Affairs (ACMA). Program: Board Certified Medical Affairs Specialist (BCMAS). Interview Summary.

article thumbnail

New Release! 200+ Page Drug Interaction Book for Virtually Nothing…

Med Ed 101

From the very beginning of Meded101 and Real Life Pharmacology, my goal has been to educate as many healthcare professionals as possible about medication safety. I’m continuing that theme with my latest project, and I want to give it away to you as cheap as Amazon will let me. My latest creation took about 6 […]. The post New Release! 200+ Page Drug Interaction Book for Virtually Nothing… appeared first on Med Ed 101.

40

More Trending

article thumbnail

Faces of Fuld: Q+A with CEO, Diane Borska

Fuld

Diane Borska, CEO and President, maintains a deep history working with Fuld + Company and has held a variety of positions within the firm spanning an almost 20-year tenure. Over the course of her career, she’s crystalized her values and emphasizes mentoring, problem-solving and client-service which is demonstrated in her leadership style. We sat down with Diane to learn more about her background, her approach to client service, and her take on Fuld + Company’s key differentiators.

61
article thumbnail

Benefits of Third Party Manufacturing of Pharmaceuticals

Fossil Remedies

ADVANTAGES OF THIRD PARTY MANUFACTURING IN PHARMA INDUSTRY. Amongst various business models used by people in the pharma manufacturing niche, third-party manufacturing is popular. Many people know that the third-party business model gives you a chance to manufacture the products even if you do not have adequate finance. However, it is not the only thing that makes it a successful model.

article thumbnail

Fuld + Company Provides Global Consumer Products Company Precise Market Sizing & Opportunity Assessment to Inform a Strategic Investment

Fuld

Background + Challenge. An international consumer goods company engaged Fuld + Company to determine the market size and assess marketplace dynamics in a large European country in support of a potential investment by leveraging unique methodology including on the ground field research. The client was unable to use syndicated research for their product in this particular country because the product is sold through traditional trade outlets like corner stores and small shops as opposed to modern tr

58
article thumbnail

How to apply global brand strategies to every customer interaction

pharmaphorum

Pharmaceutical companies spend a huge amount of time and resources on creating valuable brand strategies, but when they come to life there’s often a disconnect. Strategy and execution can easily drift apart when tactics come to life, making it harder for them to drive business and deliver on the long-term action plans to engage with healthcare professionals.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Fuld + Company Welcomes Health & Life Sciences Practice Leader, Michael Ratcliffe

Fuld

Michael Ratcliffe brings both deep industry expertise and intelligence and strategy consulting capabilities to the firm. Boston, Mass. November 26, 2019 — Fuld + Company, a global competitive strategy consultancy, today announced the recent appointment of Michael Ratcliffe as a Senior Director and Head of the Health & Life Sciences Practice.

article thumbnail

How Pharma Companies generate Franchise queries and Boost Business?

Fossil Remedies

What is the difference between the pharma sector and other sectors? Experts rate the pharma sector quite higher than others because of its huge potential for growth. Because of the tremendous progress in the Indian economy, every pharma company can expect good earnings. However, it is also essential to know about the ways of expanding and popularizing the business.

article thumbnail

TNP Student Series – Ep 008 Kim Tran

The Nontraditional Pharmacist

Kim Tran’s participation with TNP shows how taking advantage of a networking opportunity can lead to making great connections. You never know where a simple conversation will take you! Name : Kim Tran. Position: Pharmacy Student at Oregon State University. Interview Summary. Kim [00:00:00] Hi everyone and this is Kim Tran. I am a PharmD, MBA candidate at Oregon State University and you are listening to The Nontraditional Pharmacist.

article thumbnail

Why Neglecting Digital Health is a Danger for the Pharmacy Profession

The Digital Apothecary

Why Digital Health is Key for Pharmacy. And our current pursuits are just not enough. If you have been following my work, you are well aware of my passion and dedication towards getting pharmacists aware of digital health and its implications for future health practice. However, in all honesty, I think I have seen little takeoff amongst the profession by and large, and it has led me to question why that is, so let me break down my current thought process.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Not Your Typical MSL

The Nontraditional Pharmacist

Dr. Qureshi expands our understanding of the typical Medical Science Liaison role by taking a look at his position in managed markets. Great feature for those considering industry as a career option! Name: Nabeel Qureshi. Title: Medical Liaison, Managed Markets. Interview Summary. Matt [00:00:00] Matt Paterini here with The Nontraditional Pharmacist, part of the Pharmacy Podcast Network.

article thumbnail

Innovative contracting in Europe – a Trojan horse?

pharmaphorum

Overview With pricing of drugs at the centre of political and social debate, the market access and pricing environment in Europe has become increasingly challenging over the years. Innovative contracting has since become a common route to overcome these challenges and ensure timely access for patients. Focus Join us on Monday 2nd September from 15:00-16:00 BST as we discuss the future of innovative contracting with our panel of European payers.

52
article thumbnail

Harness the PharmD Power to be a Rockstar Engineer

The Nontraditional Pharmacist

Dr. David Vu innovates by using formal pharmacy training to bring additional value to roles that span other industries. Name: David Vu. Position: QA Engineer + Project Manager at Kit Check. Interview Summary. Matt [00:00:00] Matt Paterini here with The Nontraditional Pharmacist, part of the Pharmacy Podcast Network. Boy we have a great show today. Special guest, David Vu, is joining The Nontraditional Pharmacist show today and he’s a great TNP guest for a couple of reasons.

article thumbnail

How pharma marketing can stay ahead of the evolving customer journey

pharmaphorum

Overview Join our live webinar taking place on Tuesday 23rd July at 16:00 BST / 11:00 EST / 08:00 PST. Customer journeys in pharma are changing, with important implications for the marketing supply chain. How can pharmaceutical marketers capitalise on this trend and free up budget to invest in additional marketing channels? Focus New developments in data and digital are changing traditional customer journeys and forcing pharmaceutical companies to evolve in order to keep up.

article thumbnail

Lofree Wireless Calculator Review

The Digital Apothecary

Lofree Calculator. A quick review. Recently I backed Lofree wireless calculator on Kickstarter. Though I’d do a small review while waiting for other videos to be compressed for my digital health stuff.

52
article thumbnail

TNP Student Series – Ep 007 Adam Baillio

The Nontraditional Pharmacist

One of our most unique students yet… From the spotlight of performing to the pharmacy, Adam Baillio balances work and time with his (large) family. Name: Adam Baillio. Position: Pharmacy Student at Roseman University. Interview Summary. Matt [00:00:04] Matt Paterini here with The Nontraditional Pharmacist, part of the Pharmacy Podcast Network here with Adam Baillio of Roseman University today on The Nontraditional Pharmacist Student Series.

article thumbnail

Orphan medicines launch excellence: sustaining launch success

pharmaphorum

Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available. There are also a growing number of disease-focussed registries, increasing public and policy maker awareness, and significant R&D investment in orphan drugs, as well as in digital technologies to support trials and treatment.

article thumbnail

TNP Student Series – Ep 006 Aleksey Gitelson

The Nontraditional Pharmacist

We’ve all answered the same question at some point – “Why do you want to go to pharmacy school?” Most of the time the answer is what we think interviewers want to hear. But we all know some of the real reasons… We chat with Aleksey on some of these unspoken truths. Name: Aleksey Gitelson. Position: Pharmacy Student at Wilkes University.

article thumbnail

TNP Student Series – Ep 005 John David Scheper

The Nontraditional Pharmacist

Some people run from politics while others take the challenges head on. John Scheper looks to management as a springboard into his future campaign trail. Name : John David Scheper. Position: P4 Student at Presbyterian College School of Pharmacy. Interview Summary. Matt [00:00:05] Matt Paterini here with The Nontraditional Pharmacist, part of The Pharmacy Podcast Network.

article thumbnail

What's the Next Billion Dollar Pharmacy Startup going to be?

The Digital Apothecary

We Need to Think Beyond the Fill. Let me preface this by saying this post is more geared towards those outside of the pharmacy space, and wondering how to get into a potentially lucrative business area. After all, the $1 Billion PillPack acquisition by Amazon and their recent outreach to Prime members has caused quite the hubbub in the health sector.

article thumbnail

Navigating new frontiers: Ways to find space in the future RA market

pharmaphorum

Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab). The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be th

52
article thumbnail

Just What the Dr Ordered for UK Life Sciences? The 2nd Life Sciences Sector Deal

pharmaphorum

Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK government has already set out two plans for the future shape of the country’s healthcare industry: the second Life Sciences Sector Deal and the long-term plan for the NHS. With these two plans in place there are plenty of opportunities for the industry and the government to work together to keep the UK at the top of the international life sciences sector – and perhaps reach even greater heights.

52
article thumbnail

Cancer, genomics and personalised medicine: Modelling the future of oncology

pharmaphorum

The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in 2 people in the UK and 1 in 2 men/1 in 3 women in the US will experience it at some stage in their lives. And yet the picture for patients is an improving one. The move towards immunotherapies heralds much promise and this is potentially just the beginning.

52
article thumbnail

Metrics to meaning: demonstrating the value of medical communications

pharmaphorum

Medical affairs and publications teams are under increasing pressure to demonstrate effectively the success of the medical communications activities they undertake. Naturally, there are a huge number of metrics that could be used to measure and demonstrate medical communications value. The challenge is to identify, and track, those metrics that really matter, and ensure this information is interpreted effectively.

article thumbnail

OTC Tamiflu? I’ve Got Some Questions.

Med Ed 101

OTC Tamiflu may be a reality in the near future. Sanofi has purchased the over-the-counter rights for Tamiflu and is pursuing approval from the FDA. I do have some potential concerns with this medication becoming an over-the-counter option. For the pharmacology, adverse effects, drug interactions, and more on Tamiflu (oseltamivir), take a listen to this […].

FDA 40
article thumbnail

Fatal Insulin Injections and Security of Medications

Med Ed 101

I’ve worked within the walls of numerous types of settings that have access to life-saving and life-threatening medications. Whether it be at a clinic, long term care facility, assisted living facility, or hospital, it can be easy for staff to have a cavalier attitude about the access to medications. I read this VA article and […]. The post Fatal Insulin Injections and Security of Medications appeared first on Med Ed 101.

article thumbnail

2020 BCPS Exam Changes – How to Prepare

Med Ed 101

As I look ahead to help all of you prepare for the 2020 BCPS exam changes, I want to make sure that everyone is on the same page in how this might affect your studying. Questions about the exam? You MUST check out this post on FAQ’s and more. 2020 BCPS Exam Changes – Timing […]. The post 2020 BCPS Exam Changes – How to Prepare appeared first on Med Ed 101.

40
article thumbnail

Seven Common Types of Drug Interactions

Med Ed 101

There are numerous types of drug interactions. I outline some of the most common ways that drugs can affect the concentrations and activity of other drugs. Opposing Effects Many drugs will work on various receptors throughout the body. To use as an educational point, there is no better example to point to than the beta […]. The post Seven Common Types of Drug Interactions appeared first on Med Ed 101.

40
article thumbnail

The Clinical Difference Between Salmeterol and Formoterol

Med Ed 101

Both salmeterol and formoterol are considered long-acting beta-agonists. These agents have been commonly used in the setting of asthma and COPD. Each of these agents is most commonly combined with an inhaled corticosteroid. Budesonide is coupled with formoterol in the brand name product Symbicort. Salmeterol is most commonly coupled with fluticasone in the brand name […].

40
article thumbnail

Changing Glimepiride to Glipizide…to Rock the Boat or Not?

Med Ed 101

With the recent changes in the Beers Criteria, glimepiride has now been added to the list of sulfonylureas to avoid. Glipizide is the preferred agent if a sulfonylurea is to be used. This begs the question, should we recommend changing glimepiride to glipizide? In my opinion, this is definitely a gray area and an argument […]. The post Changing Glimepiride to Glipizide…to Rock the Boat or Not?

40